Immuneering Corp (NASDAQ:IMRX) has a beta value of -0.33 and has seen 0.4 million shares traded in the recent trading session. The company, currently valued at $56.16M, closed the recent trade at $1.81 per share which meant it gained $0.08 on the day or 4.54% during that session. The IMRX stock price is -345.86% off its 52-week high price of $8.07 and 44.75% above the 52-week low of $1.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.28 million shares traded. The 3-month trading volume is 2.29 million shares.

The consensus among analysts is that Immuneering Corp (IMRX) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.39.

Immuneering Corp (NASDAQ:IMRX) trade information

Sporting 4.54% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IMRX stock price touched $1.81 or saw a rise of 21.3%. Year-to-date, Immuneering Corp shares have moved -75.39%, while the 5-day performance has seen it change -16.65%. Over the past 30 days, the shares of Immuneering Corp (NASDAQ:IMRX) have changed 0.48%. Short interest in the company has seen 2.05 million shares shorted with days to cover at 1.19.

Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 86.08% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $41.0. In that case, then, we find that the latest price level in today’s session is -2165.19% off the targeted high while a plunge would see the stock gain -65.75% from the levels at last check today.

Immuneering Corp (IMRX) estimates and forecasts

Figures show that Immuneering Corp shares have underperformed across the wider relevant industry. The company’s shares have gained 22.20% over the past 6 months, with this year growth rate of 1.06%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -57.97% over the past 5 years.

IMRX Dividends

Immuneering Corp is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Immuneering Corp (NASDAQ:IMRX)’s Major holders

Insiders own 29.12% of the company shares, while shares held by institutions stand at 30.11% with a share float percentage of 42.48%. Investors are also buoyed by the number of investors in a company, with Immuneering Corp having a total of 65.0 institutions that hold shares in the company. The top two institutional holders are CITADEL ADVISORS LLC with over 1.88 million shares worth more than $2.41 million. As of 2024-06-30, CITADEL ADVISORS LLC held 6.4083% of shares outstanding.

The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.07 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.37 million and represent 3.6442% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund. As of Sep 30, 2024, the former fund manager holds about 2.37% shares in the company for having 736.19 shares of worth $1.31 million while later fund manager owns 509.13 shares of worth $0.91 million as of Sep 30, 2024, which makes it owner of about 1.64% of company’s outstanding stock.